Measuring Value in Orthopaedics: The U.S. and U.K. Perspectives

➢ Despite substantial health-care spending, both the U.S. and U.K. lack standardized, operational definitions of value in specialty care, limiting their ability to optimize patient-centric health outcomes and appropriate selection and utilization of resources. ➢ First-generation value-based specialty care models in the U.S., like the Bundled Payments for Care Improvement Initiative and Comprehensive Care for Joint Replacement, have achieved modest savings by focusing on post-acute care and procedural efficiency, without negatively impacting quality metrics. Similarly, the Getting It Right First Time initiative in the U.K. aimed to bring about higher-quality care in hospitals, at lower cost, by reducing unwanted variations in services and practices. However, there remains no true understanding of impact on value, of efficacy based on measurement of patient-centric health outcomes that matter to patients, or of whether interventions were appropriately selected in the first place. ➢ A standardized value metric, specifically the incremental cost-effectiveness ratio (ICER), is critical to measuring quality in specialty care, enabling health-care systems to compare treatment options on the basis of both cost and patient-centric outcomes. ➢ The ICER integrates quality-adjusted life years, cost data, and the duration of effectiveness, providing a framework for shared decision-making, care variation reduction, and more strategic site-of-service decisions. ➢ Health-care systems and policymakers should adopt ICER-based frameworks to transition from volume-based incentives to value-based models that support innovation, accountability, and whole-person musculoskeletal specialty care.